Global News

Novartis, IBM Watson Health partner on outcomes-based care in advanced breast cancer

Monday, June 12, 2017

Novartis announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes. The two companies will collaborate to explore development of a cognitive solution that uses real-world data and advanced analytical techniques with the aim to provide better insights on the expected outcomes of breast cancer treatment options.

[Read More]

Chiltern launches Medidata Rave Value Accelerators

Monday, June 12, 2017

Chiltern, a global CRO, has announced the release of its new Medidata Rave Value Accelerators, a system of tools designed to capture, manage and report clinical research data. The tools streamline the clinical trial process and help trial sponsors cut the time, cost and effort of bringing a new device to market.

[Read More]

ReadCoor, WAVE Life Sciences collaborate

Monday, June 12, 2017

ReadCoor, a company reinventing omics and pathology with its panomic spatial sequencing platform, and WAVE Life Sciences, a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, announced the initiation of a research collaboration to develop a registry of brain cell network maps and advance WAVE’s nucleic acid chemistry for targeted delivery to the brain.

[Read More]

ProSciento, OWL Metabolomics partner on NAFLD/NASH trial recruitment

Monday, June 12, 2017

ProSciento, a full scope clinical R&D services provider focused exclusively on metabolic diseases, and OWL Metabolomics, a biotechnology company pioneering virtual biopsy assays for the diagnosis of NAFLD/NASH, announced an exclusive, multi-year collaboration aimed at identifying individuals who are eligible for enrollment into clinical trials of therapeutic candidates to treat NAFLD (non-alcoholic fatty liver disease) and NASH (steatohepatitis).

[Read More]

Publication bias and clinical trial outcomes reporting

Monday, June 12, 2017

The Pulse on Global Trials by Matthew Howes

Last month, the world’s leading funders of medical research and international non-governmental organizations agreed to set forth new standards that will require all clinical trials they fund or support to be registered, and the results disclosed publicly within mandatory timeframes. The aim is to dramatically improve both the quality of therapies available to patients, as well as the quality of research that leads to new breakthrough. But the question remains: Will it be enough?

[Read More]